Elevated level of serum growth differentiation factor 15 is associated with oral leukoplakia and oral squamous cell carcinoma

Journal of Oral Pathology and Medicine

Volumn 43, Issue 1, 2014, Pages 28-34

  Yang, Cheng Zhe ^a   Ma, Jie ^a   Luo, Qing Qiong ^a   Neskey, David M ^b   Zhu, Dong Wang ^a   Liu, Ying ^a   Myers, Jeffrey N ^b   Zhang, Chen Ping ^a   Zhang, Zhi Yuan ^a   Zhong, Lai Ping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Growth differentiation factor 15; Induction chemotherapy; Oral leukoplakia; Oral squamous cell carcinoma; Serum

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; DOCETAXEL; FLUOROURACIL; GROWTH DIFFERENTIATION FACTOR 15; ANTINEOPLASTIC AGENT; GDF15 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; INDUCTION CHEMOTHERAPY; LEUKOPLAKIA; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUTH SQUAMOUS CELL CARCINOMA; MULTIPLE CYCLE TREATMENT; NECK DISSECTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; ADJUVANT THERAPY; AREA UNDER THE CURVE; BLOOD; CANCER GRADING; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; CASE CONTROL STUDY; COMPARATIVE STUDY; LEUKOPLAKIA, ORAL; MOUTH NEOPLASMS; PATHOLOGY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REMISSION; RETROSPECTIVE STUDY; SECONDARY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; INDUCTION CHEMOTHERAPY; LEUKOPLAKIA, ORAL; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84891835215     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/jop.12091     Document Type: Article

References (30)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705-15.
4. Vermorken BJ, Remenar E, Herpen VC, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695-704.
5. Lorch JH, Goloubeva O, Haddad RI, et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 2011; 12: 153-9.
6. Ma J, Liu Y, Huang XL, et al. Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a meta-analysis. Oral Oncol 2012; 48: 1076-84.
7. Zhong LP, Zhang CP, Ren GX, et al. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by surgery versus upfront surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol 2013; 31: 744-51.
8. Licitra L, Grandi C, Guzzo M, et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol 2003; 21: 327-33.
9. Kies MS, Boatright DH, Li G, et al. Phase II trial of induction chemotherapy followed by surgery for squamous cell carcinoma of the oral tongue in young adults. Head Neck 2012; 34: 1255-62.
10. Baek KE, Yoon SR, Kim JT, et al. Upregulation and secretion of macrophage inhibitory cytokine-1 (MIC-1) in gastric cancers. Clin Chim Acta 2009; 401: 128-33.
11. Brown DA, Ward RL, Buckhaults P, et al. Mic-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res 2003; 9: 2642-50.
12. Wallin U, Glimelius B, Jirstrom K, et al. Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer. Br J Cancer 2011; 104: 1619-27.
13. Roth P, Junker M, Tritschler I, et al. GDF-15 contributes to proliferation and immune escape of malignant gliomas. Clin Cancer Res 2010; 16: 3851-9.
14. Staff AC, Bock AJ, Becker C, Kempf T, Wollert KC, Davidson B. Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecol Oncol 2010; 118: 237-43.
15. Karan D, Chen SJ, Johansson SL, et al. Dysregulated expression of MIC-1/PDF in human prostate tumor cells. Biochem Biophys Res Commun 2003; 305: 598-604.
16. Selander KS, Brown DA, Sequeiros GB, et al. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases. Cancer Epidemiol Biomarkers Prev 2007; 16: 532-7.
17. Brown DA, Lindmark F, Stattin P, et al. Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer. Clin Cancer Res 2009; 15: 6658-64.
18. Lee DH, Yang Y, Lee SJ, et al. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res 2003; 63: 4648-55.
19. Boyle GM, Pedley J, Martyn AC, et al. Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity. J Invest Dermatol 2009; 129: 383-91.
20. Shnaper S, Desbaillets I, Brown DA, et al. Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome. Int J Cancer 2009; 125: 2624-30.
21. Zhang L, Yang X, Pan HY, et al. Expression of growth differentiation factor 15 is positively correlated with histopathological malignant grade and in vitro cell proliferation in oral squamous cell carcinoma. Oral Oncol 2009; 45: 627-32.
22. Li JZ, Pan HY, Zheng JW, et al. Benzo (a) pyrene induced tumorigenesity of human immortalized oral epithelial cells: transcription profiling. Chin Med J 2008; 121: 1882-90.
23. Schiegnitz E, Kammerer PW, Koch FP, Kruger M, Berres M, Al-Nawas B. GDF 15 as an anti-apoptotic, diagnostic and prognostic marker in oral squamous cell carcinoma. Oral Oncol 2012; 48: 608-14.
24. Ma LW, Zhou ZT, He QB, Jiang WW. Phosphorylated p120-catenin expression has predictive value for oral cancer progression. J Clin Pathol 2012; 65: 315-9.
25. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
26. Li PX, Wong J, Ayed A, et al. Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J Biol Chem 2000; 275: 20127-35.
27. Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE. Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 2001; 59: 901-8.
28. Chen SJ, Karan D, Johansson SL, et al. Prostate-derived factor as a paracrine and autocrine factor for the proliferation of androgen receptor-positive human prostate cancer cells. Prostate 2007; 67: 557-71.
29. Zhao L, Lee BY, Brown DA, et al. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Res 2009; 69: 7696-703.
30. Huang CY, Beer TM, Higano CS, et al. Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15. Clin Cancer Res 2007; 13: 5825-33.